Last $2.71 USD
Change Today -0.11 / -3.90%
Volume 3.8M
ZGNX On Other Exchanges
As of 8:10 PM 04/17/14 All times are local (Market data is delayed by at least 15 minutes).

zogenix inc (ZGNX) Snapshot

Previous Close
Day High
Day Low
52 Week High
02/13/14 - $5.19
52 Week Low
06/5/13 - $1.25
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ZOGENIX INC (ZGNX)

zogenix inc (ZGNX) Related Businessweek News

No Related Businessweek News Found

zogenix inc (ZGNX) Details

Zogenix, Inc., a pharmaceutical company, develops and commercializes therapies for the treatment of central nervous system disorders and pain. The company’s commercial products include Sumavel DosePro (sumatriptan injection), a delivery system that offers needle-free subcutaneous administration of sumatriptan for the acute treatment of migraine and cluster headache; and Zohydro, a single-entity extended-release hydrocodone for the treatment of moderate to severe chronic pain. It also develops Relday, an injectable formulation of risperidone, which is in a Phase I clinical trial to treat the symptoms of schizophrenia and bipolar disorder in adults and teenagers with 13 years of age and older. Zogenix, Inc. markets and sells its Sumavel DosePro to wholesale pharmaceutical distributors and retail pharmacies in the United States. The company was formerly known as SJ2 Therapeutics, Inc. and changed its name to Zogenix, Inc. in August 2006. Zogenix, Inc. was founded in 2006 and is headquartered in San Diego, California.

114 Employees
Last Reported Date: 03/7/14
Founded in 2006

zogenix inc (ZGNX) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $449.3K
President and Director
Total Annual Compensation: $370.2K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $335.1K
Chief Commercial Officer and Executive Vice P...
Total Annual Compensation: $335.0K
Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: $71.5K
Compensation as of Fiscal Year 2013.

zogenix inc (ZGNX) Key Developments

Zogenix Provides Update on Legal Action

Zogenix presented its case in U.S. District Court in Boston requesting an immediate order staying the ban on the U.S. Food and Drug Administration (FDA)-approved prescription drug product, Zohydro(TM) ER (hydrocodone bitartrate) extended-release capsules (CII), entered on March 27, 2014, by Massachusetts Governor Deval Patrick. Zogenix appreciates the opportunity to be heard by the court on an expedited basis. A follow-up hearing has been scheduled for April 14, 2014. The company will continue to monitor, evaluate and take appropriate actions in all states specific to Zohydro ER to ensure that all FDA-approved Schedule II prescription opioids covered by the FDA mandated Risk Evaluation Mitigation Strategy (REMS) for extended-release and long-acting opioid analgesics receive equal treatment for any rules that impact patient access and prescribing.

Zogenix, Inc. Appoints James B. Breitmeyer to its Board of Directors

Zogenix, Inc. announced that James B. Breitmeyer, M.D., Ph.D., has been appointed as a new member of the company's Board of Directors. Dr. Breitmeyer currently serves as President of Bavarian Nordic, Inc. He is also Executive Vice President of Bavarian A/S. He previously served as the acting Chief Medical Officer of Zogenix, Inc. in an advisory capacity, the Executive Vice President of Development and Chief Medical Officer of Cadence Pharmaceuticals, Inc., and the Chief Medical Officer of Applied Molecular Evolution Inc.

Zogenix, Inc. Auditor Raises 'Going Concern' Doubt

Zogenix, Inc. filed its 10-K on Mar 07, 2014 for the period ending Dec 31, 2013. In this report its auditor, Ernst & Young LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ZGNX:US $2.71 USD -0.11

ZGNX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Allergan Inc/United States $133.92 USD +2.46
Endo International PLC $57.26 USD -0.44
Eternity Healthcare Inc $0.32 USD -0.01
Sun Pharmaceutical Industries Ltd 625.05 INR 0.00
Valeant Pharmaceuticals International Inc C$134.45 CAD +0.80
View Industry Companies

Industry Analysis


Industry Average

Valuation ZGNX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 10.5x
Price/Book 20.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 8.4x

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ZOGENIX INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at